Neoadjuvant Therapy for Melanoma
Surgical Oncology Clinics of North America · 2020-07 · 29 (3) · 445-453
DOI: 10.1016/j.soc.2020.03.001 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Surgical Oncology Clinics of North America, 2020-07. Verfasst von Michael C Lowe und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Emory University School of Medicine, 1365 Clifton Road, Atlanta, GA 30322, USA. Electronic address: mlowe3@emory.edu. Hauptthemen laut MEDLINE: Molecular Targeted Therapy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
With the universal adoption of immune checkpoint blockade and agents targeting BRAF-mutated melanomas in the metastatic setting, numerous clinical trials have evaluated these agents in the neoadjuvant setting. These smaller trials have shown promising results with high pathologic response rates and acceptable safety. Larger prospective randomized trials are under way to determine if all patients with resectable metastatic disease should be receiving neoadjuvant therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Emory University School of Medicine, 1365 Clifton Road, Atlanta, GA 30322, USA. Electronic address: mlowe3@emory.edu.
- Department of Hematology and Oncology, Winship Cancer Institute, 1365 Clifton Road, Atlanta, GA 30322, USA.
Zitieren
APA
Lowe, M. C., & Kudchadkar, R. R. (2020). Neoadjuvant Therapy for Melanoma. Surgical Oncology Clinics of North America, 29(3), 445-453. https://doi.org/10.1016/j.soc.2020.03.001
Vancouver
Lowe MC, Kudchadkar RR. Neoadjuvant Therapy for Melanoma. Surgical Oncology Clinics of North America. 2020;29(3):445-453. doi:10.1016/j.soc.2020.03.001
BibTeX
@article{Lowe2020,
author = {Lowe, Michael C and Kudchadkar, Ragini R},
title = {Neoadjuvant Therapy for Melanoma},
journal = {Surgical Oncology Clinics of North America},
year = {2020},
volume = {29},
number = {3},
pages = {445--453},
doi = {10.1016/j.soc.2020.03.001}
}
EUVIMED